articleTop 1% cited
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
Journal of Clinical Oncology · 2007 · Vol. 25(15) · pp. 1960–1966
Malcolm J. Moore✉(Ontario Institute for Cancer Research)David Goldstein(Ontario Institute for Cancer Research)John Hamm(Ontario Institute for Cancer Research)Arié Figer(Ontario Institute for Cancer Research)J. Randolph Hecht(Ontario Institute for Cancer Research)Steven Gallinger(Ontario Institute for Cancer Research)H. Au(Ontario Institute for Cancer Research)P. Murawa(Ontario Institute for Cancer Research)David Walde(Ontario Institute for Cancer Research)Robert A. Wolff(Ontario Institute for Cancer Research)Daniel de Castro(Ontario Institute for Cancer Research)Robert Lim(Ontario Institute for Cancer Research)Keyue Ding(Ontario Institute for Cancer Research)Gary M. Clark(Ontario Institute for Cancer Research)Theodora Voskoglou-Nomikos(Ontario Institute for Cancer Research)Mieke Ptasynski(Ontario Institute for Cancer Research)Wendy R. Parulekar(Ontario Institute for Cancer Research)
Abstract
To our knowledge, this randomized phase III trial is the first to demonstrate statistically significantly improved survival in advanced pancreatic cancer by adding any agent to gemcitabine. The recommended dose of erlotinib with gemcitabine for this indication is 100 mg/d.
Pancreatic and Hepatic Oncology ResearchNeuroendocrine Tumor Research AdvancesColorectal Cancer Treatments and StudiesGemcitabineErlotinibMedicineInternal medicinePancreatic cancerErlotinib HydrochlorideOncologyHazard ratioAdverse effectPlacebo
MeSH terms
Erlotinib HydrochlorideGemcitabineAdenocarcinomaAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsDeoxycytidineDouble-Blind MethodFemaleHumansInternational AgenciesMaleMiddle AgedPancreatic Neoplasms
Citations
3,845
FWCI
119.48
field-weighted impact
References
49
Percentile
100%
vs. same field & year
Citations per year
Cited by
Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer
Clinical Cancer Research · 2008 · 1,303 citations
Recent progress in pancreatic cancer
CA A Cancer Journal for Clinicians · 2013 · 934 citations
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
New England Journal of Medicine · 2011 · 7,636 citations
The Pancreas Cancer Microenvironment
Clinical Cancer Research · 2012 · 1,296 citations
Wild-Type <i>KRAS</i> Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Journal of Clinical Oncology · 2008 · 3,144 citations
Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer
BMC Cancer · 2008 · 431 citations
Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative Therapy
Annals of Surgical Oncology · 2006 · 872 citations
Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology · 2015 · 1,308 citations
References
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Journal of Clinical Oncology · 1997 · 5,865 citations
Cancer Statistics, 2005
CA A Cancer Journal for Clinicians · 2005 · 5,459 citations
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
New England Journal of Medicine · 2004 · 11,455 citations
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
JNCI Journal of the National Cancer Institute · 2000 · 15,689 citations
Related articles
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
Journal of Clinical Oncology · 2007 · 3,845 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.